CTA Adverse Event Reporting 2 — Questions and Answers
Question 1: Which regulatory agency requires IND safety reports (MedWatch Form FDA 3500A) for serious unexpected adverse drug reactions in the US?
- FDA (Correct answer)
- EMA
- ICH
- OHRP
Correct answer: FDA
The FDA requires IND safety reports using MedWatch Form FDA 3500A for serious unexpected adverse drug reactions occurring in US-regulated trials.
Question 2: A subject in a clinical trial experiences a Grade 3 elevation in liver enzymes that resolves without sequelae. How should this be classified?
- Adverse Event (AE) only
- Serious Adverse Event (SAE) (Correct answer)
- Adverse Drug Reaction (ADR)
- Expected Adverse Event
Correct answer: Serious Adverse Event (SAE)
A Grade 3 laboratory abnormality that requires medical intervention meets the 'medically significant' criterion for classification as a Serious Adverse Event.
Question 3: What is the primary purpose of expedited safety reporting in clinical trials?
- To complete the clinical study report faster
- To allow regulators to assess benefit-risk and protect trial participants promptly (Correct answer)
- To notify the trial sponsor of protocol deviations
- To update the informed consent form immediately
Correct answer: To allow regulators to assess benefit-risk and protect trial participants promptly
Expedited reporting enables regulators to rapidly assess the benefit-risk profile of the investigational product and take protective action for trial participants.
Question 4: Under ICH E6(R2), who is ultimately responsible for the timely reporting of SAEs to the sponsor?
- The CTA at the site
- The IRB/IEC
- The Principal Investigator (Correct answer)
- The Clinical Research Organization
Correct answer: The Principal Investigator
ICH E6(R2) places ultimate responsibility on the Principal Investigator to report SAEs to the sponsor immediately or within the timeframe specified by the protocol.
Question 5: A SUSAR must be reported to the FDA within how many calendar days if the event is fatal or life-threatening?
- 7 calendar days (Correct answer)
- 15 calendar days
- 30 calendar days
- 45 calendar days
Correct answer: 7 calendar days
Fatal or life-threatening unexpected serious adverse reactions (SUSARs) must be reported to the FDA within 7 calendar days of the sponsor first receiving information.
Question 6: Which term describes an adverse event that a qualified medical expert considers to have a reasonable causal relationship to the investigational medicinal product?
- Adverse Event (AE)
- Adverse Drug Reaction (ADR) (Correct answer)
- Serious Adverse Event (SAE)
- Unexpected Adverse Event
Correct answer: Adverse Drug Reaction (ADR)
An Adverse Drug Reaction (ADR) specifically implies a causal relationship between the event and the investigational product, distinguishing it from a general AE.
Question 7: What action should a CTA take if they discover that an SAE was not reported within the required timeframe?
- Wait until the next monitoring visit to address it
- Immediately notify the sponsor and document the deviation (Correct answer)
- Amend the protocol to extend reporting timelines
- Instruct the site to back-date the report
Correct answer: Immediately notify the sponsor and document the deviation
A late SAE report is a protocol deviation that must be immediately escalated to the sponsor and fully documented to ensure transparency and regulatory compliance.
CTA Adverse Event Reporting 2
Which regulatory agency requires IND safety reports (MedWatch Form FDA 3500A) for serious unexpected adverse drug reactions in the US?